Tech Company Financing Transactions
Nammi Therapeutics Funding Round
On 8/6/2024, Nammi Therapeutics announced Series B funding from Myeloma Investment Fund.
Transaction Overview
Company Name
Announced On
8/6/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Investors
Proceeds Purpose
The investment came prior to the planned start of a first-in-human Phase 1 study of its lead program, QXL138AM, in patients with locally advanced unresectable and/or metastatic solid tumors and multiple myeloma.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
10940 Wilshire Blvd 600
Los Angeles, CA 90024
USA
Los Angeles, CA 90024
USA
Phone
Undisclosed
Website
Email Address
Overview
Nammi Therapeutics, Inc. is an immunotherapy company developing first in class products for the treatment of cancer. Seeking to extend the benefits of immunotherapy to all cancer patients, Nammi has identified three key principles that have limited immunotherapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Stover
VP - Operations
Joseph Rice
Browse more venture capital transactions:
Prev: 8/6/2024: Redacted venture capital transaction
Next: 8/6/2024: Artax Biopharma venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs